カポジ肉腫治療の世界市場:産業分析、市場規模、市場シェア、成長、動向、予測

◆英語タイトル:Kaposi Sarcoma Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
◆商品コード:TMR60931
◆発行会社(調査会社):Transparency Market Research
◆発行日:2016年8月11日
◆ページ数:131
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:産業未分類
◆販売価格オプション(消費税別)
Single UserUSD5,795 ⇒換算¥643,245見積依頼/購入/質問フォーム
Multi UserUSD8,795 ⇒換算¥976,245見積依頼/購入/質問フォーム
Corporate LicenseUSD11,795 ⇒換算¥1,309,245見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTransparency Market Research社の日本における正規販売代理店です。Transparency Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、カポジ肉腫治療の世界市場について調査・分析し、産業分析、カポジ肉腫治療の世界市場規模、市場シェア、成長、市場動向、予測データを含め、以下の構成でお届けいたします。
・カポジ肉腫治療の世界市場:序文
・カポジ肉腫治療の世界市場:エグゼクティブサマリー
・カポジ肉腫治療の世界市場:市場概要・動向
・カポジ肉腫治療の世界市場:セグメント別市場規模・分析
・カポジ肉腫治療の世界市場:地域別市場規模・分析
・カポジ肉腫治療の世界市場:関連企業分析
【レポートの概要】

Kaposi sarcoma is a soft tissue sarcoma that develops in connective tissues, blood vessels, fibrous tissues, and muscles. It is a malignant, multi-centric, neoplastic vascular proliferation, characterized by the development of bluish-red cutaneous nodules on the feet. According to the U.S. Center for Disease Control and Prevention (CDC), Kaposi sarcoma is considered an acquired immune deficiency syndrome (AIDS) defining disease. This report analyzes the current and future prospects of the Kaposi sarcoma market based on type of treatment, distribution channel, and geography.
The report is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of major Kaposi sarcoma therapies in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, and various international and national databases. The report provides estimated market size in terms of US$ Mn for each treatment method, distribution channel, and geography for the period 2014 to 2024, considering the macro and micro environmental factors. The revenue generated from each treatment method was calculated by considering number of patients, average cost of the drugs, trends in the industry, distribution channel trends, and adoption rate of therapy across all the geographies. The revenues generated from services, including surgery and radiation therapy were calculated based on the costs and average number of procedures.
The market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on type of treatment, distribution channel, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints, and opportunities that influence the Kaposi sarcoma market in the current and future scenario. The report provides the list of drugs in various stages of clinical trials, which are expected to shape the future course of the market, through pipeline analysis. The report also provides value chain analysis of the market that describes the sequence of activities from drug manufacturing to the final destination, which is the end user.
Market share analysis is provided to highlight percentage share of the major players operating in the market. All these factors will help market players to decide business strategies and plans to strengthen their position in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Market forecast for major countries in these regions have also been provided for the forecast period.
In addition, this report includes a list of recommendations to aid new entrants and established players in taking strategic initiatives to strengthen their presence in the market. The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the Kaposi sarcoma market report are Bristol – Myers Squibb, Eli Lilly and Co., Hoffman-La Roche, Inc., GlaxoSmithKline plc, Johnson & Johnson, Pfizer, Inc., and Schering Plough Corporation (Merck & Co., Inc.)
The global Kaposi Sarcoma market has been segmented as follows:
• Kaposi Sarcoma Market, By Type of Treatment
o Chemotherapy
 Liposomal Anthracyclines
 Alkaloids
o Immunotherapy
o HAART

• Kaposi Sarcoma Market, By Distribution Channel
o Hospitals
o Cancer Research Institutes
o Multispecialty Clinics
o Ambulatory Surgical Centers

• Kaposi Sarcoma Market, By Geography
o North America
 U.S.
 Canada
o Europe
 U.K.
 Germany
 Rest of Europe
o Asia Pacific
 China
 Japan
 India
 Australia
 Rest of Asia Pacific
o Latin America
 Brazil
 Mexico
 Rest of Latin America
o Middle East and Africa
 U.A.E.
 South Africa
 Rest of Middle East and Africa

【レポートの目次】

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Kaposi sarcoma market

4. Market Overview
4.1. Introduction
4.2. Key market indicators
4.3. Regulatory scenario
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
4.5. Value Chain Analysis

5. Global Kaposi Sarcoma Market, by Treatment
5.1. Key Findings
5.2. Global Kaposi Sarcoma Market, by Type of Treatment, (US$ Mn), 2014–2024
5.2.1. Chemotherapy
5.2.1.1. Liposomal Anthracyclines
5.2.1.2. Alkaloids
5.2.2. Immunotherapy
5.2.3. HAART
5.3. Global Kaposi Sarcoma Market Attractiveness, by Treatment, 2015

6. Global Kaposi Sarcoma Market, by Distribution Channel
6.1. Global Kaposi Sarcoma Market, by Distribution Channel, (US$ Mn), 2014–2024
6.1.1. Hospitals
6.1.2. Cancer Research Institutes
6.1.3. Multispecialty Clinics
6.1.4. Ambulatory Surgical Centers
6.2. Global Kaposi Sarcoma Market Attractiveness, by Distribution Channel, 2015

7. Global Kaposi Sarcoma Market, by Region
7.1. Global Kaposi Sarcoma Market, by Region, (US$ Mn), 2014–2024
7.1.1. North America
7.1.2. Europe
7.1.3. Asia Pacific
7.1.4. Latin America
7.1.5. Middle East and Africa
7.2. Global Kaposi Sarcoma Market Attractiveness, by Region, 2015

8. Global Kaposi Sarcoma Market, Pipeline Analysis
8.1. Overview
8.2. List of Early Stage Drug Candidates

9. North America Kaposi Sarcoma Market
9.1. North America Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
9.1.1. Chemotherapy
9.1.2. Immunotherapy
9.1.3. HAART
9.2. North America Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
9.2.1. Hospitals
9.2.2. Cancer Research Institutes
9.2.3. Multispecialty Clinics
9.2.4. Ambulatory Surgical Centers
9.3. North America Kaposi Sarcoma Market, by Country, (US$), 2014–2024
9.3.1. U.S.
9.3.2. Canada
9.4. Market Attractiveness, by Type of Treatment, 2015
9.5. Market Attractiveness, by Country, 2015

10. Europe Kaposi Sarcoma Market
10.1. Europe Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
10.1.1. Chemotherapy
10.1.2. Immunotherapy
10.1.3. HAART
10.2. Europe Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
10.2.1. Hospitals
10.2.2. Cancer Research Institutes
10.2.3. Multispecialty Clinics
10.2.4. Ambulatory Surgical Centers
10.3. EuropeKaposi Sarcoma Market, by Country, (US$), 2014–2024
10.3.1. U.K.
10.3.2. Germany
10.3.3. Rest of Europe
10.4. Market Attractiveness, by Type of Treatment, 2015
10.5. Market Attractiveness, by Country, 2015

11. Asia Pacific Kaposi Sarcoma Market
11.1. Asia Pacific Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
11.1.1. Chemotherapy
11.1.2. Immunotherapy
11.1.3. HAART
11.2. Asia Pacific Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
11.2.1. Hospitals
11.2.2. Cancer Research Institutes
11.2.3. Multispecialty Clinics
11.2.4. Ambulatory Surgical Centers
11.3. Asia Pacific Kaposi Sarcoma Market, by Country, (US$), 2014–2024
11.3.1. China
11.3.2. Japan
11.3.3. India
11.3.4. Australia
11.3.5. Rest of Asia Pacific
11.4. Market Attractiveness, by Type of Treatment, 2015
11.5. Market Attractiveness, by Country, 2015

12. Latin America Kaposi Sarcoma Market
12.1. Latin America Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
12.1.1. Chemotherapy
12.1.2. Immunotherapy
12.1.3. HAART
12.2. Latin America Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
12.2.1. Hospitals
12.2.2. Cancer Research Institutes
12.2.3. Multispecialty Clinics
12.2.4. Ambulatory Surgical Centers
12.3. Latin America Kaposi Sarcoma Market, by Country, (US$), 2014–2024
12.3.1. Brazil
12.3.2. Mexico
12.3.3. Rest of Latin America
12.4. Market Attractiveness, by Type of Treatment, 2015
12.5. Market Attractiveness, by Country, 2015

13. Middle East and Africa Kaposi Sarcoma Market
13.1. Middle East and Africa Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
13.1.1. Chemotherapy
13.1.2. Immunotherapy
13.1.3. HAART
13.2. Middle East and Africa Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
13.2.1. Hospitals
13.2.2. Cancer Research Institutes
13.2.3. Multispecialty Clinics
13.2.4. Ambulatory Surgical Centers
13.3. Middle East and Africa Kaposi Sarcoma Market, by Country, (US$), 2014–2024
13.3.1. U.A.E.
13.3.2. South African Republic
13.3.3. Rest of Middle East and Africa
13.4. Market Attractiveness, by Type of Treatment, 2015
13.5. Market Attractiveness, by Country, 2015

14. Global Kaposi Sarcoma Market Analysis, By Services
14.1. Radiation Therapy
14.2. Surgery

15. Competitive Landscape
15.1. Growth-Share Matrix of Companies, 2015
15.2. Market Share Analysis, 2015
15.3. Company Profiles
15.3.1. Bristol-Myers Squibb Company
15.3.1.1. Company Overview
15.3.1.2. Business Overview
15.3.1.3. Product Portfolio
15.3.1.4. Financial Overview
15.3.1.5. Recent Developments
15.3.2. Eli Lilly and Company
15.3.2.1. Company Overview
15.3.2.2. Business Overview
15.3.2.3. Product Portfolio
15.3.2.4. Financial Overview
15.3.2.5. Recent Developments
15.3.3. F. Hoffmann-La Roche Ltd.
15.3.3.1. Company Overview
15.3.3.2. Business Overview
15.3.3.3. Product Portfolio
15.3.3.4. Financial Overview
15.3.3.5. Recent Developments
15.3.4. GlaxoSmithKline plc
15.3.4.1. Company Overview
15.3.4.2. Business Overview
15.3.4.3. Product Portfolio
15.3.4.4. Financial Overview
15.3.4.5. Recent Developments
15.3.5. Johnson & Johnson
15.3.5.1. Company Overview
15.3.5.2. Business Overview
15.3.5.3. Product Portfolio
15.3.5.4. Financial Overview
15.3.5.5. Recent Developments
15.3.6. Merck & Co., Inc.
15.3.6.1. Company Overview
15.3.6.2. Business Overview
15.3.6.3. Product Portfolio
15.3.6.4. Financial Overview
15.3.6.5. Recent Developments
15.3.7. Pfizer, Inc.
15.3.7.1. Company Overview
15.3.7.2. Business Overview
15.3.7.3. Product Portfolio
15.3.7.4. Financial Overview
15.3.7.5. Recent Developments

16. Recommendations

List of Figures

Figure 1 Market Segmentation
Figure 2 Global Kaposi Sarcoma Market Revenue by Type of Treatment, (US$ Mn), 2014–2024
Figure 3 Global Kaposi Sarcoma Market Revenue, by Distribution Channel, (US$ Mn), 2014–2024
Figure 4 Global Kaposi Sarcoma Market Revenue, by Geography, (US$ Mn), 2014–2024
Figure 5 Value Chain Analysis
Figure 6 Global Liposomal Anthracyclines Market for Kaposi Sarcoma, (US$ Mn), 2014–2024
Figure 7 Global Alkaloids Market, (US$ Mn), 2014–2024
Figure 8 Global Kaposi Sarcoma Market Attractiveness, by Treatment, 2015
Figure 9 Global Kaposi Sarcoma Market Attractiveness, by Distribution Channel, 2015
Figure 10 Global Kaposi Sarcoma Market Attractiveness, by Region, 2015
Figure 11 North America Kaposi Sarcoma Market Attractiveness, by Type of Treatment, 2015
Figure 12 North America Kaposi Sarcoma Market Attractiveness, by Country, 2015
Figure 13 Europe Kaposi Sarcoma Market Attractiveness, by Treatment, 2015
Figure 14 Europe Kaposi Sarcoma Market Attractiveness, by Country, 2015
Figure 15 Asia Pacific Kaposi Sarcoma Market Attractiveness, by Type of Treatment, 2015
Figure 16 Asia Pacific Kaposi Sarcoma Market Attractiveness, by Country, 2015
Figure 17 Latin America Kaposi Sarcoma Market Attractiveness, by Type of Treatment, 2015
Figure 18 Latin America Kaposi Sarcoma Market Attractiveness, by Country, 2015
Figure 19 Middle East and Africa Kaposi Sarcoma Market Attractiveness, by Treatment, 2015
Figure 20 Middle East and Africa Kaposi Sarcoma Market Attractiveness, by Country, 2015
Figure 21 Growth Share Matrix, By Key Players (2015)
Figure 22 Market Share Analysis by Key Companies (Value %), 2015
Figure 23 Bristol-Myers Squibb Company Financial Overview (US$ Mn), 2013–2015
Figure 24 Bristol-Myers Squibb Company Revenues by Segment, 2015 (%)
Figure 25 Eli Lilly and Company Financial Overview (US$ Mn), 2013–2015
Figure 26 Eli Lilly and Company Human Pharmaceutical Products sub-segment revenues 2015 (%)
Figure 27 F. Hoffmann-La Roche Ltd. Financial Overview (US$ Mn), 2013–2015
Figure 28 F. Hoffmann-La Roche Ltd. Pharmaceutical sub-segment revenues 2015 (%)
Figure 29 GlaxoSmithKline plc Financial Overview (US$ Mn), 2013–2015
Figure 30 Johnson & Johnson Financial Overview (US$ Mn), 2013–2015
Figure 31 Johnson & Johnson Pharmaceutical sub-segment revenues, 2015 (%)
Figure 32 Merck & Co., Inc. Financial Overview (US$ Mn), 2013–2015
Figure 33 Merck & Co., Inc. Pharmaceutical sub-segment revenues, 2015 (%)
Figure 34 Pfizer, Inc. Financial Overview (US$ Mn), 2013–2015
Figure 35 Pfizer, Inc. Global Vaccines, Oncology, and Consumer Healthcare sub-segment Revenues 2015 (%)

List of Tables

Table 1 Global Kaposi Sarcoma Market, By Type of Treatment Snapshot (2014 – 2024)
Table 2 Global Kaposi Sarcoma Market, By Distribution Channel, Snapshot (2014 – 2024)
Table 3 Global Kaposi Sarcoma Market, By Geography Snapshot (2014 – 2024)
Table 4 Global Kaposi Sarcoma Market, by Type of Treatment, (US$ Mn), 2014–2024
Table 5 Global Kaposi Sarcoma Market, by Distribution Channel, (US$ Mn), 2014–2024
Table 6 Global Kaposi Sarcoma Market, by Region, (US$ Mn), 2014–2024
Table 7 Pipeline Analysis
Table 8 North America Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
Table 9 North America Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014– 2024
Table 10 North America Kaposi Sarcoma Market, by Country, (US$), 2014–2024
Table 11 Europe Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
Table 12 Europe Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
Table 13 Europe Kaposi Sarcoma Market, by Country, (US$), 2014–2024
Table 14 Asia Pacific Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
Table 15 Asia Pacific Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
Table 16 Asia Pacific Kaposi Sarcoma Market, by Country, (US$), 2014–2024
Table 17 Latin America Kaposi Sarcoma Market, by Type of Treatment (US$), 2014–2024
Table 18 Latin America Kaposi Sarcoma Market, by Distribution Channel (US$), 2014–2024
Table 19 Latin America Kaposi Sarcoma Market, by Country (US$), 2014–2024
Table 20 Middle East & Africa Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
Table 21 Middle East & Africa Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
Table 22 Middle East & Africa Kaposi Sarcoma Market, by Country, (US$), 2014–2024
Table 23 Radiotherapy and Surgery (Average cost and Number of procedures)



【レポートのキーワード】

カポジ肉腫治療、化学療法、免疫療法、HAART

★調査レポート[カポジ肉腫治療の世界市場:産業分析、市場規模、市場シェア、成長、動向、予測]販売に関する免責事項
★調査レポート[カポジ肉腫治療の世界市場:産業分析、市場規模、市場シェア、成長、動向、予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆